BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 2033427)

  • 21. Hodgkin's disease in childhood and adolescence: results of chemotherapy-radiotherapy in clinical stages IA-IIB.
    Cramer P; Andrieu JM
    J Clin Oncol; 1985 Nov; 3(11):1495-502. PubMed ID: 3903063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial.
    Björkholm M; Axdorph U; Grimfors G; Merk K; Johansson B; Landgren O; Svedmyr E; Mellstedt H; Holm G
    Ann Oncol; 1995 Nov; 6(9):895-9. PubMed ID: 8624292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data.
    Prosnitz LR; Farber LR; Kapp DS; Scott J; Bertino JR; Fischer JJ; Cadman EC
    J Clin Oncol; 1988 Apr; 6(4):603-12. PubMed ID: 2451712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
    Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
    J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment with MOPP or ChlVPP chemotherapy only for all stages of childhood Hodgkin's disease.
    Ekert H; Waters KD; Smith PJ; Toogood I; Mauger D
    J Clin Oncol; 1988 Dec; 6(12):1845-50. PubMed ID: 3058876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
    Carde P; Hagenbeek A; Hayat M; Monconduit M; Thomas J; Burgers MJ; Noordijk EM; Tanguy A; Meerwaldt JH; Le Fur R
    J Clin Oncol; 1993 Nov; 11(11):2258-72. PubMed ID: 7693881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two cycles of MOPP and radiotherapy for stage III1A and stage III1B Hodgkin's disease.
    Henkelmann GC; Hagemeister FB; Fuller LM
    J Clin Oncol; 1988 Aug; 6(8):1293-302. PubMed ID: 3411342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
    J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease.
    Andrieu JM; Ifrah N; Payen C; Fermanian J; Coscas Y; Flandrin G
    J Clin Oncol; 1990 Jul; 8(7):1148-54. PubMed ID: 2193118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pediatric Hodgkin's disease.
    Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
    J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results.
    Hancock BW; Vaughan Hudson G; Vaughan Hudson B; Haybittle JL; Bennett MH; MacLennan KA; Jelliffe AM
    Br J Cancer; 1991 Apr; 63(4):579-82. PubMed ID: 2021542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of subdiaphragmatic Hodgkin's disease: long-term results and side effects.
    Cutuli B; Petit T; Hoffstetter S; Velten M; Dufour P; Giron C; Lederlin P; Jung GM; Bergerat JP; Maloisel F; Bey P; Oberling F
    Oncol Rep; 1998; 5(6):1513-8. PubMed ID: 9769397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B.
    Canellos GP; Petroni GR; Barcos M; Duggan DB; Peterson BA
    J Clin Oncol; 1995 Aug; 13(8):2005-11. PubMed ID: 7636541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy.
    Santoro A; Bonadonna G; Valagussa P; Zucali R; Viviani S; Villani F; Pagnoni AM; Bonfante V; Musumeci R; Crippa F
    J Clin Oncol; 1987 Jan; 5(1):27-37. PubMed ID: 2433409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
    Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
    J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Four cycles of chemotherapy and regional radiation therapy for clinical early-stage and intermediate-stage Hodgkin's disease.
    Straus DJ; Yahalom J; Gaynor J; Myers J; Koziner B; Caravelli J; Lee BJ; Nisce LZ; McCormick B; Bajorunas D
    Cancer; 1992 Feb; 69(4):1052-60. PubMed ID: 1370915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease.
    Tannir N; Hagemeister F; Velasquez W; Cabanillas F
    J Clin Oncol; 1983 Jul; 1(7):432-9. PubMed ID: 6199478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.